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BN/GRP = bombesin/gastrin-releasing peptide; IL = interleukin; MCP-1 = monocyte chemoattractant protein-1; RA = rheumatoid arthritis; SP =
substance P; TNF-α = tumor necrosis factor-α; VIP = vasoactive intestinal polypeptide.
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Abstract
Many studies have shown that modulation of cytokine function is
effective in ameliorating symptoms of rheumatoid arthritis. Neuro-
peptides have recently been shown to have powerful effects on the
production and release of cytokines and have also been shown to
exert potent proinflammatory and anti-inflammatory effects in
animal models of inflammatory diseases. An analysis of cytokine
and neuropeptide content of synovial fluid from patients with
rheumatoid arthritis has revealed a significant correlation between
two neuropeptides, bombesin/gastrin-releasing peptide and
substance P, and the proinflammatory cytokine interleukin-6 as well
as the erythrocyte sedimentation rate. These findings provide
further evidence for a role of neuropeptides and cytokines in the
pathophysiology of rheumatoid arthritis, as well as suggesting
additional approaches for the development of novel therapeutic
interventions.
A lack of a comprehensive understanding of the patho-
genesis of rheumatoid arthritis (RA) has hampered the
development of novel therapeutic approaches to the treat-
ment of this disease. In the current issue of this journal,
Grimsholm and colleagues [1] have investigated a role for
neuropeptides in the pathology of RA. Although many
different cell types, such as macrophages and synoviocytes,
have long been known to be involved in RA, it has recently
been realized that the peripheral nervous system has a key
role in modulating the severity of RA [2–4]. Synovial tissue is
richly innervated with neuropeptide-containing primary
afferent and sympathetic neurons [5–7] and there is evidence
that the release of these neuropeptides powerfully influences
the severity of chronic inflammatory diseases, including RA
[8,9]. Grimsholm and colleagues [1] evaluated the relation-
ship between synovial fluid levels of neuropeptides, inflam-
matory cytokines and duration of disease in patients with RA.
Among the five neuropeptides and three cytokines assayed,
they observed a significant correlation between the levels of
just two neuropeptides, bombesin/gastrin-releasing peptide
(BN/GRP) and substance P (SP) with inflammatory cytokines.
It is well known that proinflammatory cytokines have a
fundamental role in the development and maintenance of RA
and other inflammatory diseases. Cytokines such as IL-1,
tumor necrosis factor-α (TNF-α) and IL-6 are produced
locally in synovial tissue, as well as systemically, where it has
been hypothesized they are the principal effectors for the
pathological and clinical manifestations of RA [10]. Indeed,
several novel therapies that have recently been developed or
are currently undergoing clinical trials for RA target several of
these cytokines, such as TNF-α (etanercept, adalimumab and
infliximab), IL-1 (anakinra) and IL-6 (MRA) [11–14]. However,
although there is evidence that anti-cytokine therapies might
be effective for patients with RA, it is likely that targeting a
single cytokine might benefit only specific subgroups of
patients with RA. Other proinflammatory mediators, such as
neuropeptides, are also likely to be involved in RA [15–19],
but the precise relationship between neuropeptides, cyto-
kines and RA has received little attention.
Grimsholm and colleagues [1] have hypothesized that
proinflammatory neuropeptides have a key role in the
pathogenesis and maintenance of RA, and they report in this
issue that there is a correlation between the synovial
concentration of two neuropeptides, BN/GRP and SP, and
proinflammatory cytokines. The RA patient population was
divided in to ‘early RA’ (less than 12 months’ disease
duration) and ‘longstanding RA’ (more than 12 months’
disease duration). Although calcitonin gene-related peptide,
neuropeptide Y, vasoactive intestinal polypeptide (VIP),
BN/GRP and SP were all detectable in synovial fluid, only
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with BN/GRP was there a significant difference between
early and longstanding RA (higher in early RA). SP and
BN/GRP were significantly higher than in healthy controls,
which was consistent with this group’s previous findings [19].
Synovial concentrations of the inflammatory cytokines TNF-α,
IL-6 and monocyte chemoattractant protein-1 (MCP-1) were
detectable in most or all of the patients with RA (no
difference was observed between the two disease groups).
Importantly, further analysis of the data revealed that in
longstanding RA but not in early RA the synovial levels of
BN/GRP were tightly correlated with the synovial levels of
both IL-6 and TNF-α, as well as with serum levels of soluble
TNF receptor 1 (which binds to and neutralizes TNF-α).
Furthermore, there was an inter-relationship between levels of
SP, TNF-α and MCP-1, as well as levels of SP, BN/GRP and
IL-6. The other neuropeptides evaluated were not correlated
with any of the cytokines measured. The authors also noted
that synovial BN/GRP and SP were correlated with a measure
of RA disease state, namely erythrocyte sedimentation rate.
The evidence for the involvement of neuropeptides in
inflammatory diseases has focused predominantly on a
proinflammatory role for SP [15,17], as well as an immuno-
modulatory role for neuropeptide Y [16] and an anti-inflam-
matory role for VIP [8]. The mechanism of action of these
neuropeptides in modulating inflammatory diseases is, at
least in part, due to their ability to affect cytokine production.
For example, SP increases production of the proinflammatory
cytokines TNF-α, IL-6 and IL-1β [20], whereas VIP inhibits the
production of the proinflammatory cytokines TNF-α, IL-6 and
IL-12, and stimulates the production of the anti-inflammatory
cytokines IL-10 and IL-1Ra [21]. The major novel finding by
Grimsholm and colleagues is that synovial BN/GRP, with SP,
is closely associated with IL-6, TNF-α and RA disease
activity. The authors speculate that, in addition to SP,
BN/GRP might stimulate cytokine production from immune
cells to contribute to RA pathology, and that pharmacological
modulation of BN/GRP and/or SP should be considered as
potential new avenues for RA therapy.
The findings for a novel role of BN/GRP in RA, and further
support for a role for SP, are clearly important, but several
questions must be addressed before firm conclusions can be
drawn. A fundamental question is what the causal relation-
ship between BN/GRP and cytokines are; unlike some other
neuropeptides, for which both in vivo and in vitro evidence
has been provided for their ability to produce both pro-
inflammatory and anti-inflammatory cytokines from immune
cells (see above), this has not yet been reported for BN/GRP.
Although the authors tentatively suggest that BN/GRP and
SP might both stimulate cytokine production, BN/GRP levels
were higher in the patients with early RA than in those with
longstanding RA (SP was the same in both groups), which
could indicate that BN/GRP might be involved more in the
development than in the maintenance of RA. Further studies
with selective BN/GRP receptor antagonists, such as
RC-3940-II, in animal models of RA will probably provide
crucial information about the role of this peptide in RA.
There is a clear need for an expansion in the therapeutic
armamentarium for RA given the inadequacy of current
therapies for many patients, and the study by Grimsholm and
colleagues have opened up a potential novel therapeutic
avenue for targeting the underlying pathology not only in RA
but also possibly in other autoimmune diseases.
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